update

Berlin-Based Neurotech Startup Nuuron Closes €3.5 milion Seed Round

Berlin, October 31, 2024

Activating the Memory System of the Brain with Software to Treat Alzheimer’s Disease

Nuuron is developing a fully digital Alzheimer’s therapy based on a proprietary neuromodulation technology. Nuuron’s algorithms produce ultra-high frequency, digital-photonic stimuli that activate the Memory System of Alzheimer’s patients, aiming to improve memory formation and memory recall. This digital disease-modifying therapy uses the retina as interface into the brain and employs advanced VR and AR technologies for stimulation delivery.

Oversubscribed Round and Consortium of Renowned Investors

The Berlin-based neurotech startup Nuuron has raised €3.5 million in an oversubscribed seed financing round. The round is led by High-Tech Gründerfonds (HTGF) and includes investors such as IBB Ventures, caesar., the Business Angel Club Berlin, other business angels and family offices. In addition, Nuuron entered a strategic partnership with RoX Health, a subsidiary of the pharma and diagnostics group Roche.

Clinical Trials with Charité and DZNE – Market Entry in Europe and the U.S.

Nuuron will use this funding for animal studies in collaboration with the German Center for

Neurodegenerative Diseases (DZNE) and a clinical trial with Alzheimer’s patients at Charité and to advance product development. Additionally, market entry preparations start in Europe and the U.S.

Nuuron Has Hacked the Neural Code of Memory

“Our scientists have succeeded in hacking the neural code of memory, enabling us to develop a

digital drug to treat Alzheimer’s Disease. We call it the Memory Pacemaker – an effective therapy, prescribed by doctors and reimbursed by health insurances,” explains Dr. Markus Müschenich, co-founder of Nuuron.

A New Therapy Option for 100+ Million Alzheimer’s Patients

Currently, over 55 million people worldwide live with Alzheimer’s Disease and other dementias, a number expected to rise to 139 million by 2050. The market for Alzheimer’s therapies was estimated at USD 5.8 billion in 2023, with a projected increase to USD 11.4 billion by 2032.

Nuuron Demonstrates the Immense Potential of Digital Drugs

"We at RoX Health have supported Nuuron from the very beginning in a strategic collaboration, as we recognized the immense potential of their technology early on. Nuuron's innovative approach demonstrates the possibilities that digital therapeutics offer and how we can treat complex diseases even more effectively in the future.” Dr. Robert Schnitzler, CEO, RoX Health, Berlin & Head Digital Health Innovation, Roche Pharma AG

About Nuuron

Nuuron was founded by Fabian Queisner and Dr. Markus Müschenich. The scientific work is lead by Priv.-Doz. Dr. Julian Keil. Nuuron’s dedicated team unites specialists across neuroscience, medicine, neuroinformatics, machine learning, and public health."

About HTGF - High-Tech Gründerfonds

HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF has financed more than 750 start-ups and achieved over 180 successful exits. Fund investors in the public-private partnership include the German Federal Ministry of Economics and Climate Action, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.

About IBB Ventures

IBB Ventures (www.ibbventures.de) has been providing venture capital to innovative Berlin-based companies since 1997 and has established itself as the market leader in early-stage financing in Berlin. The funds are primarily used for the development and market launch of innovative products or services as well as for business concepts in the creative industries. In addition to our two VC funds for Berlin-based technology and creative industries startups with a combined volume of EUR 90 million, our impact VC fund with a volume of EUR 30 million has been in the investing stage since 2022. All our funds are backed by Investitionsbank Berlin (IBB) and the European Regional Development Fund (ERDF), administered by the State of Berlin. IBB Ventures has already invested in more than 260 Berlin-based creative and technology companies; in consortia with partners, the start-ups received more than €1.8 billion, of which IBB Ventures invested more than €275 million as lead, co-lead or co-investor. IBB Ventures is the parent brand for the VC activities of IBB Beteiligungsgesellschaft.

Contact Person

Dr. Hannah-Sophie Braun
IBB Ventures
Bundesallee 210
10719 Berlin

Tel: +49 (0)30 2125 3201
Mail: info@ibbventures.de